Spanish Prospective Registry of Hydra THV for Transcatheter Aortic Valve Implantation
Key facts
- Where
- Aravaca, Barcelona, Fuencarral-El Pardo, L'Hospitalet de Llobregat, Salamanca, Santiago de Compostela, Seville, and Toledo, SpainSee the 8 sites
Where in Spain
- Hospital Clínico San CarlosAravaca, SpainContact: RAUL MORENO GOMEZ, MD, PhDTaking people
- Hospital de la Santa Creu i Sant PauBarcelona, SpainContact: RAUL MORENO GOMEZ, MD, PhDTaking people
- Hospital Universitario La PazFuencarral-El Pardo, SpainContact: RAUL MORENO GOMEZ, MD, PhDTaking people
- Hospital Universitari de BellvitgeL'Hospitalet de Llobregat, SpainContact: RAUL MORENO GOMEZ, MD, PhDTaking people
- Hospital Universitari de SalamancaSalamanca, SpainContact: RAUL MORENO GOMEZ, MD, PhDTaking people
- Hospital Clínico Universitario de SantiagoSantiago de Compostela, SpainContact: RAUL MORENO GOMEZ, MD, PhDTaking people
- Hospital Universitario Virgen del RocioSeville, SpainContact: RAUL MORENO GOMEZ, MD, PhDTaking people
- Hospital General Universitario de ToledoToledo, SpainContact: RAUL MORENO GOMEZ, MD, PhDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Fundación EPIC
- Trial code
- NCT07566624
- Record updated
- 10 November 2026
- Original description
This study is designed to evaluate the success rate of transfemoral implantation of the Hydra THV biological aortic valve prosthesis in patients with severe symptomatic aortic stenosis. The device is used in accordance with its Instructions for Use as a CE-marked transcatheter heart valve system.Read full original descriptionShow less
This study is designed to evaluate the success rate of transfemoral implantation of the Hydra THV biological aortic valve prosthesis in patients with severe symptomatic aortic stenosis. The device is used in accordance with its Instructions for Use as a CE-marked transcatheter heart valve system.
The study will assess procedural success, device performance, and early clinical outcomes following implantation. Patients undergoing transcatheter aortic valve replacement (TAVR) via the transfemoral approach will be followed to evaluate safety and effectiveness outcomes, including short- and mid-term clinical follow-up.
Inclusion: Participants who meet ALL of the following conditions will be included:; Age ≥ 18 years and; Severe aortic stenosis with indication for aortic valve replacement in which a Hydra THV device is implanted according to the instructions for use; and; Signed informed consent.
Exclusion: Patients who do NOT meet ANY of the following conditions will be included:; Aortic stenosis patients who are not candidates for Hydra THV device implantation or in whom implantation of this device is performed for an indication other than aortic stenosis (especially pure native aortic valve insufficiency). Patients in whom the Hydra THV device is implanted to treat patients with degenerated aortic bioprostheses may be included in the study; Express refusal by the participant to participate in the study; Participants in randomised clinical trials who have not reached the research endpoint; Pregnant and/or breastfeeding women.